Korean Drug Financials
014570 Stock | KRW 4,370 150.00 3.32% |
Korean |
Understanding current and past Korean Drug Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Korean Drug's financial statements are interrelated, with each one affecting the others. For example, an increase in Korean Drug's assets may result in an increase in income on the income statement.
Please note, the presentation of Korean Drug's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Korean Drug's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Korean Drug's management manipulating its earnings.
Korean Drug Stock Summary
Korean Drug competes with HJ ShipBuilding, Nam Hwa, ENERGYMACHINERY KOREA, Semyung Electric, and Formetal. Korean Drug Co., Ltd. researches, develops, manufactures, and markets medicines for treating human illness in South Korea. Korean Drug Co., Ltd. was founded in 1980 and is headquartered in Seoul, South Korea. KOREAN DRUG is traded on Korean Securities Dealers Automated Quotations in South Korea.Instrument | Korea Stock View All |
Exchange | KOSDAQ |
ISIN | KR7014570006 |
Business Address | 34 Nonhyeon-ro 28-gil, |
Sector | Healthcare |
Industry | Pharmaceuticals |
Benchmark | Dow Jones Industrial |
Website | www.nicepharma.com |
Phone | 82 2 529 6100 |
Currency | KRW - South Korean Won |
You should never invest in Korean Drug without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Korean Stock, because this is throwing your money away. Analyzing the key information contained in Korean Drug's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Korean Drug Key Financial Ratios
Korean Drug's financial ratios allow both analysts and investors to convert raw data from Korean Drug's financial statements into concise, actionable information that can be used to evaluate the performance of Korean Drug over time and compare it to other companies across industries.Korean Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Korean Drug's current stock value. Our valuation model uses many indicators to compare Korean Drug value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Korean Drug competition to find correlations between indicators driving Korean Drug's intrinsic value. More Info.Korean Drug Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The ratio of Return On Equity to Return On Asset for Korean Drug Co is about 217.99 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Korean Drug by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Korean Drug's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Korean Drug Systematic Risk
Korean Drug's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Korean Drug volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Korean Drug correlated with the market. If Beta is less than 0 Korean Drug generally moves in the opposite direction as compared to the market. If Korean Drug Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Korean Drug is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Korean Drug is generally in the same direction as the market. If Beta > 1 Korean Drug moves generally in the same direction as, but more than the movement of the benchmark.
Korean Drug Thematic Clasifications
Korean Drug Co is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
Drugs | View |
Korean Drug December 4, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Korean Drug help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Korean Drug Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Korean Drug Co based on widely used predictive technical indicators. In general, we focus on analyzing Korean Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Korean Drug's daily price indicators and compare them against related drivers.
Information Ratio | (0.28) | |||
Maximum Drawdown | 6.39 | |||
Value At Risk | (2.75) | |||
Potential Upside | 1.78 |
Complementary Tools for Korean Stock analysis
When running Korean Drug's price analysis, check to measure Korean Drug's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Korean Drug is operating at the current time. Most of Korean Drug's value examination focuses on studying past and present price action to predict the probability of Korean Drug's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Korean Drug's price. Additionally, you may evaluate how the addition of Korean Drug to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
CEOs Directory Screen CEOs from public companies around the world | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |